However, because of the interest in using systemic NF-κB inhibitors as mono-therapy or in combination with other chemotherapeutic drugs in clinical trials in ovarian cancer patients [35], possible side effects that limit drug efficacy, promote toxicity or have frankly deleterious effects are highly relevant clinically. This evidence concerns the gene NFKB1 and ovarian carcinoma.